Empowering India’s Future on Safer Roads
Reading Time: 2 minutes India grapples with a staggering road safety crisis, recording over 1.7 lakh fatalities annually, with young individuals making up a significant portion of these tragedies. Alarmingly, 29 children lose their lives daily due to road accidents, highlighting an urgent need for structured education and awareness
Visma Announces all-cash voluntary recommended public takeover offer for Penneo
Reading Time: 12 minutes Company Release no. 19/2024 Copenhagen, Denmark, 29 November 2024 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. Penneo
VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond
Reading Time: 3 minutes Shanghai, China: VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand
Crayon Appointed as AWS Authorized Distributor for the European Economic Area, including Switzerland
Reading Time: 2 minutes Crayon builds on its existing distribution expertise to enable partners across new regions to innovate and scale on Amazon Web Services (AWS). Crayon, a global leader in IT services and innovation, today announced its appointment as an AWS Authorized Distributor for
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
Reading Time: 7 minutes Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1
Notice to attend the extraordinary general meeting in OssDsign AB
Reading Time: 29 minutes The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the extraordinary general meeting at 10:00 am on Wednesday 18 December 2024 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024
Reading Time: < 1 minute Stock Exchange Release 28.11.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2024 Date 28.11.2024 Exchange transaction Buy Share class FSKRS Amount 300 Average price/share 14.8196 EUR Highest price/share 14.8200 EUR Lowest price/share
Europi Property Group AB (publ) successfully issues senior unsecured green bonds
Reading Time: 2 minutes NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT.
The board of Peptonic resolves, subject to the approval a subsequent general meeting, on a rights issue of units of approximately SEK 26.5 million
Reading Time: 9 minutes NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PEPTONIC MEDICAL AB
Reading Time: 11 minutes N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB, and in case of any discrepancies between the Swedish and the English translation, the Swedish text shall